Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy
Pro-inflammatory cytokines decrease while nerve-protective pathways activate, supporting small fiber regeneration and improved microcirculation
CaloMist Nasal Spray (cyanocobalamin, USP) label
For maximum support, take as directed every day
Bacteriostatic saline containing benzyl alcohol decreases the pain of intradermal injection
It is not intended for human consumption, medical use, or therapeutic application
